From April 21 to 23, the 23rd World Pharmaceutical Raw Materials Exhibition in Japan (CPHI Japan 2026) was grandly held at the Ariake International Convention and Exhibition Center in Tokyo. Ms.Zeng, Director of International Development at Jiudian Hongyang, led her team to showcase a range of specialized APIs and excipients as well as customized pharmaceutical solutions. At this premier industry event in the Asia-Pacific pharmaceutical APIs sector, the team accurately addressed the core demands of the Japanese and East Asian markets, securing several significant cooperation agreements.

      CPHI Japan serves as a premier professional exhibition in the Asia-Pacific pharmaceutical APIs sector, targeting core markets including Japan, South Korea, and Taiwan, China. It serves as the flagship event of the CPHI global exhibition series and a vital platform for pharmaceutical companies to deepen their presence in Japan's and the broader Asia-Pacific's high-end pharmaceutical supply chains while facilitating technical exchanges and business collaborations. As the world's third-largest pharmaceutical market, Japan maintains robust demand for premium pharmaceutical ingredients and innovative technologies. The stringent industry entry standards make successful integration into Japan's pharmaceutical supply chain a key indicator of global recognition for pharmaceutical enterprises.
        In recent years, affected by stricter environmental regulations and insufficient production capacity in Japan, local APIs and excipients manufacturers have frequently faced production stoppages. The local market has an urgent need for compliant, stable, and high-quality international suppliers, which has brought a historic opportunity for high-quality Chinese pharmaceutical companies to expand overseas. Accurately targeting this market pain point, Jiudian Hongyang has made advance plans. The participation in this exhibition was led by Director Zeng, with efficient collaboration across the entire core team, including R&D, production, registration, and business. The company has long focused on the R&D and production of specialized APIs and excipients, as well as customized supporting services, continuously refining its core product capabilities. Currently, the company has made phased progress in the R&D and launch of several core products, and the commercialization process is steadily advancing. With its industry-leading R&D innovation capabilities, a complete quality management system, and a stable supply chain, Jiudian Hongyang has gained widespread recognition in the domestic and international pharmaceutical industries, gradually establishing a reliable and high-quality Chinese pharmaceutical brand image.

During the exhibition, Jiudian Hongyang's booth, with its strong product capabilities and professional display services, attracted a large number of Japanese pharmaceutical companies, industry experts, and professional visitors. The exhibiting team and visiting guests held in-depth discussions on core topics such as customized product development, in-depth technical cooperation, and regional market expansion. Clear cooperation intentions were reached for several products, including aluminum magnesium metasilicate, aluminum magnesium hydroxide, and allantoin aluminum, laying a solid foundation for the company's deep layout in the Asia-Pacific market.

After the exhibition, the Jiudian Hongyang team immediately visited its core partners in Japan to focus on CDMO cooperation projects for specific matchmaking and in-depth discussions. This visit further narrowed the distance between the two parties, reaching a high degree of consensus on project progress milestones, technical cooperation details, and long-term strategic cooperation plans. This laid a solid foundation for the efficient implementation of subsequent cooperation projects and the deepening of a long-term mutually beneficial strategic partnership.

This appearance at CPHI Japan is not only an important measure for Jiudian Hongyang to cultivate the high-end pharmaceutical market in East Asia and deepen regional industrial synergy, but also a key practice for the company to implement its globalization development strategy and promote high-quality development. Looking to the future, Jiudian Hongyang will always adhere to its original aspiration as a pharmaceutical company, continue to take technological innovation as its core engine, anchor itself to international first-class quality standards, continuously deepen the collaboration across the entire industry chain with global partners, and continuously expand in-depth cooperation in the global pharmaceutical industry chain, continuously empowering the high-quality development of the global pharmaceutical industry and writing more brilliant chapters for Chinese brands in the global pharmaceutical market.